Drug manufacturer Most Active: Merck & Co. (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Raptor Pharmaceutical (NASDAQ:RPTP)

Bristol-Myers Squibb Co (NYSE:BMY)’s ipilimumab, or Yervoy as it’s commercially known, was dubbed the skin cancer ‘wonder’ drug by the media when it was licensed for use in the UK in 2011. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.33 percent to $54.00 Friday on volume of 8.05million shares. The intra-day range of the stock was $53.88 to $54.44. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $89.11billion.

Senior Analyst Glenn Novarro of RBC Capital Markets foresees Johnson & Johnson (NYSE:JNJ) experiencing strong pharmaceutical growth and a recovery of consumer sales growth in 2014, followed by outperformance in operating margins in 2015. Johnson & Johnson (NYSE:JNJ)’s stock on Mar 14, 2014 reported a decrease of -0.20% to the closing price of $92.81. Its fifty two weeks range is $78.50-$95.99. The total market capitalization recorded $262.50billion. The overall volume in the last trading session was 7.34million shares. In its share capital, JNJ has 2.82billion outstanding shares.

MDMA — or 3,4-methylenedioxy-N-methamphetamine — was first synthesized a century ago by chemists at Merck & Co. Inc. (NYSE:MRK), which patented it as a precursor to a blood-clotting medication. Merck & Co. Inc. (NYSE:MRK) stock performance was -0.16% in last session and finished the day at $55.70. Traded volume was 12.12million shares in the last session and the average volume of the stock remained 12.35million shares. The beta of the stock remained 0.32. Merck & Co., Inc. (NYSE:MRK) insider ownership is 0.03%.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) plummeted nearly 23 percent today after the biotechnology company posted a non-GAAP loss of $0.19 per share for the fourth quarter that was wider than a loss of $0.16 per share estimated by analysts. On Friday, shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) dropped -23.94% to close the day at $11.25. Company monthly performance is recorded as -27.37%. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) quarterly revenue growth is -21.27%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone